{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:48:21Z","timestamp":1791856101795,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.contraception.2009.08.010","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T13:07:04Z","timestamp":1254402424000},"page":"8-15","source":"Crossref","is-referenced-by-count":46,"title":["Review of clinical experience with estradiol in combined oral contraceptives"],"prefix":"10.1016","volume":"81","author":[{"given":"Franca","family":"Fruzzetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2009.08.010_bib1","series-title":"Contraceptive Technology","first-page":"773","article-title":"Contraceptive efficacy","author":"Trussell","year":"2004"},{"key":"10.1016\/j.contraception.2009.08.010_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/09513599609041268","article-title":"A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene","volume":"10","author":"Dusterberg","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2009.08.010_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13625180008500375","article-title":"Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone","volume":"5","author":"Huber","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2009.08.010_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/dmi046","article-title":"New progestagens for contraceptive use","volume":"12","author":"Sitruk-Ware","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2009.08.010_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0010-7824(97)00123-6","article-title":"Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest","volume":"56","author":"Spona","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.010_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0960-0760(94)90146-5","article-title":"Estrogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects","volume":"48","author":"Krattenmacher","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2009.08.010_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0038-1646528","article-title":"A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters","volume":"61","author":"Lindberg","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.contraception.2009.08.010_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1471-0528.1978.tb14894.x","article-title":"The comparative effects of a synthetic and a 'natural' oestrogen on the haemostatic mechanism in patients with primary amenorrhoea","volume":"85","author":"Toy","year":"1978","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2009.08.010_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.contraception.2004.03.004","article-title":"Effect of four oral contraceptives on hemostatic parameters","volume":"70","author":"Wiegratz","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.010_bib10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(80)91550-0","article-title":"Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content","volume":"1","author":"Bottiger","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2009.08.010_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/01443619509015499","article-title":"The risk of venous thromboembolism associated with low oestrogen oral contraceptives","volume":"14","author":"Farmer","year":"1995","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2009.08.010_bib12","first-page":"CD003989","article-title":"20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception","author":"Gallo","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2009.08.010_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.010_bib14","series-title":"Clinical Gynecologic Endocrinology and Infertility","first-page":"866","author":"Speroff","year":"2005"},{"key":"10.1016\/j.contraception.2009.08.010_bib15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1530\/acta.0.0870855","article-title":"Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation","volume":"87","author":"Bostofte","year":"1978","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.contraception.2009.08.010_bib16","first-page":"1","article-title":"Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects","volume":"107","author":"Helgason","year":"1982","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"10.1016\/j.contraception.2009.08.010_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0002-9378(82)90218-6","article-title":"Comparison of pharmacodynamic properties of various estrogen formulations","volume":"144","author":"Mashchak","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.010_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0010-7824(80)90010-4","article-title":"A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens","volume":"21","author":"World Health Organization Task Force on Oral Contraception","year":"1980","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.010_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1600-0412.1981.tb00038.x","article-title":"Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation","volume":"60","author":"Serup","year":"1981","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2009.08.010_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(79)91525-3","article-title":"Natural oestrogens for oral contraception","volume":"2","author":"Serup","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2009.08.010_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0015-0282(16)56210-4","article-title":"Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol","volume":"60","author":"Wenzl","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2009.08.010_bib22","first-page":"183","article-title":"Efficacy and tolerability of a combined oral contraceptive containing 17 beta-estradiol and desogestrel (Abstract)","volume":"1","author":"Kivinen","year":"1996","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2009.08.010_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1471-0528.1979.tb11276.x","article-title":"Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol","volume":"86","author":"Astedt","year":"1979","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2009.08.010_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/00016348709015732","article-title":"Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel","volume":"66","author":"Schubert","year":"1987","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2009.08.010_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0010-7824(96)00201-6","article-title":"The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days","volume":"54","author":"Csemiczky","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.08.010_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0378-5122(88)90023-0","article-title":"New natural oestradiol\/cyproterone acetate oral contraceptive for pre-menopausal women","volume":"10","author":"Hirvonen","year":"1988","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2009.08.010_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0378-5122(94)00856-3","article-title":"Oral contraceptive containing natural estradiol for premenopausal women","volume":"21","author":"Hirvonen","year":"1995","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2009.08.010_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0378-5122(82)90064-0","article-title":"Pharmacokinetic and pharmacological features of oestradiol valerate","volume":"4","author":"Dusterberg","year":"1982","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2009.08.010_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF03190010","article-title":"Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study","volume":"24","author":"Timmer","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.contraception.2009.08.010_bib30","series-title":"Handbook of Experimental Pharmacology, Estrogens and Antiestrogens II","first-page":"261","article-title":"Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens","author":"Kuhnz","year":"1999"},{"key":"10.1016\/j.contraception.2009.08.010_bib31","series-title":"Extragenital effects of oral contraceptives","first-page":"39","article-title":"A new low-dose oral contraception containing ethinylestradiol, estradiol and dienogest: first experience of its clinical use","author":"Kovacs","year":"1997"},{"key":"10.1016\/j.contraception.2009.08.010_bib32","first-page":"105","article-title":"Alternatives of the replacement of ethinylestradiol by natural 17beta-estradiol in dienogest-containing oral contraceptives","volume":"35","author":"Hoffmann","year":"1999","journal-title":"Drugs of Today"},{"key":"10.1016\/j.contraception.2009.08.010_bib33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0940-2993(98)80034-1","article-title":"Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives","volume":"50","author":"Hoffmann","year":"1998","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.contraception.2009.08.010_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/13625189909085259","article-title":"The pharmacological profile of dienogest","volume":"4","author":"Oettel","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2009.08.010_bib35","first-page":"3","article-title":"The preclinical and clinical profile of dienogest. A short overview","volume":"35","author":"Oettel","year":"1999","journal-title":"Drugs Today"},{"key":"10.1016\/j.contraception.2009.08.010_bib36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.steroids.2007.10.003","article-title":"Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile","volume":"73","author":"Sasagawa","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2009.08.010_bib37","first-page":"499","article-title":"A 19-norprogestin without 17alpha-ethinyl group I: dienogest from a pharmacokinetic point of view","volume":"31","author":"Oettel","year":"1995","journal-title":"Drugs Today"},{"key":"10.1016\/j.contraception.2009.08.010_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1358\/mf.2002.24.10.802320","article-title":"Clinical findings with the oral contraceptive combination ethinylestradiol\/dienogest in the Czech Republic","volume":"24","author":"Golbs","year":"2002","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.contraception.2009.08.010_bib39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1358\/mf.2002.24.10.802320","article-title":"Clinical findings with the oral contraceptive combination ethinylestradiol\/dienogest in Poland","volume":"24","author":"Golbs","year":"2002","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.contraception.2009.08.010_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/13625189909040810","article-title":"The efficacy and tolerability of Valette: a postmarketing surveillance study","volume":"4","author":"Zimmermann","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2009.08.010_bib41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.contraception.2008.05.004","article-title":"Ovulation inhibition with four variations of a four-phasic estradiol valerate\/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies","volume":"78","author":"Endrikat","year":"2008","journal-title":"Contraception"},{"issue":"4 Suppl","key":"10.1016\/j.contraception.2009.08.010_bib42","first-page":"15S","article-title":"Efficacy and tolerability of a new oral contraceptive containing estradiol and dienogest","volume":"111","author":"Nahum","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"Suppl","key":"10.1016\/j.contraception.2009.08.010_bib43","first-page":"94","article-title":"Bleeding patterns and cycle control with a novel four-phasic combined oral contraceptive containing estradiol valerate and dienogest","volume":"13","author":"Parke","year":"2008","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2009.08.010_bib44","first-page":"i78","article-title":"Comparative effects of a four-phasic regimen of estradiol valerate\/dienogest versus ethinylestradiol\/levonorgestrel on haemostatic parameters","volume":"23","author":"Parke","year":"2008","journal-title":"Hum Reprod Update"},{"issue":"4 Suppl","key":"10.1016\/j.contraception.2009.08.010_bib45","first-page":"12S","article-title":"Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest","volume":"111","author":"Parke","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.08.010_bib46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1210\/jcem-38-4-602","article-title":"The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone","volume":"38","author":"Longcope","year":"1974","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782409003849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782409003849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:48:08Z","timestamp":1739368088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782409003849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0010782409003849"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2009.08.010","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}